Close Menu

BioMarker Strategies

The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.

The company has received grant funding for diagnostic development projects, and is also seeking its first pharma service customers to provide nearer-term revenue.

The funding will go towards developing the PathMap companion diagnostic technology, based on the firm's SnapPath platform. 

BioMarker Strategies has appointed Jerry Parrott as its new president, CEO, and director, effective immediately.

NEW YORK (GenomeWeb News) – BioMarker Strategies today announced it is being granted a $1.5 million Small Business Innovation Research Phase II award to further develop its companion diagnostic for melanoma.

Sera Prognostics has named Ilia Ichetovkin vice president of lab operations where he will head development and deployment of the company's CLIA lab services and the commercial launch of its proteomic test to predict preterm birth risk.

Third Rock Ventures has hired Felix Frueh as an entrepreneur-in-residence.

NEW YORK (GenomeWeb News) – Tissue-based cancer diagnostics shop BioMarker Strategies has raised $1.1 million of a targeted $4 million round, a company executive confirmed.

Pairings: Jun 1, 2011

Premium

Kevin King, Frank Witney, Douglas Clark, Glen Miller

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.